SITC Resource Library

Enduring materials from the SITC Immuno-Oncology Drug Development Summit were presented in Boston on Sept. 30 - Oct.1 2024.

Program Organizers

• Alexandra Snyder, MD – Generate Biomedicines
• Amy McKee, MD – AstraZeneca
• Jon M.Wigginton, MD – Bright Peak Therapeutics
• Luisa Salter-Cid, PHD – Flagship Pioneering
• Pedro J.Romero, MD – Novigenix
  

Program Details

The SITC Immuno-Oncology Drug Development Summit will educate and engage the entire immuno-oncology (IO) community on the next wave of IO therapeutics and ensure that active, innovative, new therapies are rapidly and appropriately moved into clinical testing. This program will be a key forum for continuing exploration and discussion of best practices for modern IO drug development, including study design, regulatory pathways and emerging technologies.

Learning Objectives

Upon completion of the program, participants will be able to:

1. Describe key informational resources and implement best practices regarding the development of immuno-oncology therapeutics beginning with selection of mouse models, multicellular models, organoids and toxicology approaches
2. Foster relationships between regulatory agencies, industry members, and academic investigators to develop effective strategies for the development of immuno-oncology therapeutics through discussion of case studies, lessons learned and looking ahead across mechanisms (including deeper dives into immune cell engagers, cell therapies and AI for IO drug development)
3. Integrate scientific and regulatory objectives to develop preclinical and clinical strategies that drive efficient development of immuno-oncology therapeutics
4. Design effective clinical trials specific to immuno-oncology therapeutics (including trial designs, dose-finding, and endpoints) that reflect regulatory expectations and requirements